Aquestive NDA for Anaphylm Accepted by FDA
Detailed price information for Aquestive Therapeutics Inc (AQST-Q) from The Globe and Mail including charting and trades.
Model output · Signal date 2026-10-20
Aquestive Therapeutics, Inc. (AQST) Stock Forecast Oct. 20, 2026
Analysis updated on Oct. 20, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Rating · 90D
▲ Bullish
Exact rating locked
90-day forecast
Sign up free to reveal
30-day forecast
Total
Rank in coverage
Top 35%
of 4020 stocks scored
Rank correlation · 90D
1.0%
Spearman, 358 dates
Market Cap
$481M
small-cap · #60 of 60 peers
Summary
Aquestive Therapeutics, Inc. (AQST) stock forecast summary
Our AI ranks Aquestive Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Aquestive Therapeutics, Inc. is a small-cap company with a market capitalization of $481M. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For AQST, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 1.0%, measured on 358 forecast dates between 2022-08-02 and 2026-07-22 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 7.0%, measured on 400 forecast dates between 2022-08-02 and 2026-09-18. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.9% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-20 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, AQST included.
Follow AQST freePrice
AQST price chart and AI forecast
Cross-section · 2026-10-20
How AQST ranks among 4020 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Aquestive Therapeutics, Inc. (AQST) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | AQST | Rank |
|---|---|---|
| Market Cap | $481M | 60/60 |
| EPS | $-0.82 | – |
| Revenue/Share | $0.43 | – |
| FCF/Share | $-0.37 | – |
Profitability & Margins
| Metric | AQST | Rank |
|---|---|---|
| ROA | -59.2% | 39/42 |
| ROIC | -45.6% | 36/46 |
| Gross Margin | 67.0% | 30/36 |
| Operating Margin | -97.5% | 34/39 |
| Net Margin | -144.6% | 30/34 |
| EBT Margin | -144.6% | 42/46 |
| Tax Rate | 0.0% | – |
Financial Health
| Metric | AQST | Rank |
|---|---|---|
| Current Ratio | 7.19x | 15/59 |
| Quick Ratio | 6.74x | 3/44 |
| Interest Coverage | -3.6x | 24/36 |
| Working Capital | $102M | 52/59 |
Cash Flow
| Metric | AQST | Rank |
|---|---|---|
| Operating Cash Flow | -$45M | 40/59 |
| Free Cash Flow | -$46M | 34/50 |
| Capital Spending | -$580K | 9/50 |
| FCF/Sales | -85.0% | 39/42 |
| CapEx/Sales | 1.1% | 29/42 |
Operational Efficiency
| Metric | AQST | Rank |
|---|---|---|
| Asset Turnover | 0.41x | 27/40 |
| Receivables Turnover | 5.8x | 14/38 |
| Inventory Turnover | 2.4x | 16/36 |
| Fixed Assets Turnover | 13.7x | 15/41 |
| Days Sales Outstanding | 63 days | 24/38 |
| Days Inventory | 151 days | 21/36 |
| Payables Period | 184 days | 11/26 |
| Cash Conversion Cycle | 30 days | 18/24 |
Income Statement
| Metric | AQST | Rank |
|---|---|---|
| Total Revenue | $54M | 45/46 |
| Operating Income | -$53M | 31/51 |
| Net Income | -$78M | 27/45 |
| R&D Expense | $16M | 58/58 |
| SG&A Expense | $73M | 41/41 |
| Cost of Goods Sold | $18M | 34/37 |
Dividend & Shareholder Information
| Metric | AQST | Rank |
|---|---|---|
| Shares Outstanding | 126M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $118M | |
| Cash & Short-term Investments | $98M | |
| Accounts Receivable | $9M | |
| Inventory | $7M | |
| Total Liabilities | $189M | |
| Short-term Debt | $8M |
Quarterly Financial Reports
AQST quarterly financials and insider trading
Industry Peers · Pharmaceutical Preparations
Aquestive Therapeutics, Inc. (AQST) industry peers
Companies classified under the same SEC industry code as Aquestive Therapeutics, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| AQST Aquestive Therapeutics, Inc. | ▲ | $481M |
| LLY Eli Lilly & Co | ▼ | $1.17T |
| JNJ Johnson & Johnson | ▼ | $611.61B |
| ABBV Abbvie Inc. | ▼ | $499.53B |
| MRK Merck & Co., Inc. | ▶ | $354.36B |
| NVS Novartis Ag | ▼ | $286.60B |
| AZN Astrazeneca Plc | ▼ | $254.12B |
| ABT Abbott Laboratories | ▼ | $182.39B |
| NVO Novo Nordisk A S | ▼ | $170.74B |
| PFE Pfizer Inc | ▼ | $167.80B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▼ | $127.22B |
| BMY Bristol Myers Squibb Co | ▼ | $120.17B |
| GSK Gsk Plc | ▼ | $99.78B |
| SNY Sanofi | ▼ | $97.55B |
| REGN Regeneron Pharmaceuticals, Inc. | ▶ | $80.86B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $61.26B |
| TEVA Teva Pharmaceutical Industries Ltd | ▼ | $48.14B |
| ONC Beone Medicines Ltd. | ▲ | $42.08B |
| ZTS Zoetis Inc. | ▼ | $32.80B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▶ | $31.22B |
| RPRX Royalty Pharma Plc | ▼ | $26.58B |
| ROIV Roivant Sciences Ltd. | ▶ | $25.06B |
| GMAB Genmab A/S | ▲ | $24.77B |
| UTHR United Therapeutics Corp | ▼ | $23.30B |
| VTRS Viatris Inc | ▼ | $20.97B |
| INSM Insmed Inc | ▶ | $20.81B |
| ASND Ascendis Pharma A/S | ▶ | $15.16B |
| JAZZ Jazz Pharmaceuticals Plc | ▼ | $13.53B |
| BBIO Bridgebio Pharma, Inc. | ▶ | $13.28B |
| SMMT Summit Therapeutics Inc. | ▲ | $12.42B |
| CORT Corcept Therapeutics Inc | ▲ | $12.12B |
| ELAN Elanco Animal Health Inc | ▶ | $11.74B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.92B |
| BMRN Biomarin Pharmaceutical Inc | ▶ | $10.58B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▼ | $10.33B |
| CYTK Cytokinetics Inc | ▲ | $8.71B |
| PTGX Protagonist Therapeutics, Inc | ▶ | $8.70B |
| TGTX Tg Therapeutics, Inc. | ▲ | $8.46B |
| AXSM Axsome Therapeutics, Inc. | ▲ | $8.16B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $8.08B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.47B |
| IONS Ionis Pharmaceuticals Inc | ▶ | $7.38B |
| PRAX Praxis Precision Medicines, Inc. | ▲ | $7.26B |
| ALKS Alkermes Plc. | ▶ | $7.21B |
| ABVX Abivax S.A. | ▼ | $6.87B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▼ | $6.20B |
| AMRX Amneal Pharmaceuticals, Inc. | ▶ | $6.18B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▶ | $6.07B |
| LGND Ligand Pharmaceuticals Inc | ▼ | $5.93B |
| BLTE Belite Bio, Inc | ▲ | $5.80B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.34B |
| COGT Cogent Biosciences, Inc. | ▲ | $5.21B |
| PTCT Ptc Therapeutics, Inc. | ▶ | $5.14B |
| MANE Veradermics, Inc | ▲ | $5.11B |
| ORKA Oruka Therapeutics, Inc. | ▲ | $4.93B |
| ERAS Erasca, Inc. | ▲ | $4.76B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.52B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.17B |
| EWTX Edgewise Therapeutics, Inc. | ▲ | $4.12B |
| ARQT Arcutis Biotherapeutics, Inc. | ▲ | $4.01B |
Where AQST sits on the market map
Life Sciences · Pharmaceutical Preparations
News
Aquestive Therapeutics, Inc. (AQST) stock news
The Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Are Out And Analysts Have Published New Forecasts
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Aquestive Therapeutics, Inc. Announces FDA Acceptance Of Anaphylm NDA Resubmission And PDUFA Goal Date Of March 16, 2027
Aquestive submitted the resubmission to the Anaphylm NDA on September 16, 2026, following the August 2026 announcement of positive topline results from human factors and pharmacokinetic (PK) studies ...
FAQ
Aquestive Therapeutics, Inc. (AQST) stock forecast FAQ
What is the Aquestive Therapeutics, Inc. (AQST) stock forecast?
Our AI ranks Aquestive Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Aquestive Therapeutics, Inc. stock predictions?
For AQST, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 1.0%, measured on 358 forecast dates between 2022-08-02 and 2026-07-22 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 7.0%, measured on 400 forecast dates between 2022-08-02 and 2026-09-18. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Aquestive Therapeutics, Inc. forecasts updated?
Aquestive Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 20, 2026.
Which companies are Aquestive Therapeutics, Inc.'s industry peers?
60 issuers in our coverage, AQST included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.